Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S reports new 104-week data from its pivotal ApproaCH Trial in children with achondroplasia treated once weekly with TransCon CNP (navepegritide). The data show children maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second treatment year.
The randomized, double-blind, placebo-controlled trial enrolled 84 children aged 2–11 years, with a 52-week placebo-controlled phase followed by an open-label extension to Week 104. TransCon CNP, a prodrug of C-type natriuretic peptide, is designed for continuous CNP exposure to counter overactive FGFR3 signaling.
In February 2026, TransCon CNP was approved by the U.S. FDA under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. A Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.
Ascendis Pharma A/S reports that its board granted 22,480 warrants to certain employees under its Articles of Association. Each warrant allows the holder to buy one ordinary share at an exercise price of US $240.52, matching the ADS closing price on the grant date.
Twenty-five percent of the warrants vest one year after the grant, with the remaining 75% vesting monthly over the following three years, subject to continued service and possible earlier vesting on certain exit events. After this grant, warrants to subscribe for an additional 1,644,153 shares remain available for future grants.
Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026. The filing lists the sale method as a warrant exercise for $2,400,000.00 and indicates trading on Nasdaq. The transaction type is listed as cash.
Ascendis Pharma A/S proposes sale of 94,000 American Depository Shares. The filing lists a warrant exercise by the issuer for 94,000 ADS on 03/05/2026 with cash consideration. The filing also records prior sales of 86,860 ADS by Jan Moller Mikkelsen on 01/13/2026.